Back to all events
05 Aug 2019
  • Victorian Comprehensive Cancer Centre
  • University of Melbourne
  • Monash University

Monday Lunch Live with Dr C. Glenn Begley

Opportunities for Australian drug discovery and development

How can Australia compete in the global market of cancer drug discovery and development? This is the big question Dr C. Glenn Begley, expert in clinical haematology and medical oncology, will cover in his Monday Lunch Live presentation.

Dr C. Glenn Begley will present the challenges and opportunities for drug discovery and development in Melbourne and Australia and how BioCurate was created to combat this.

BioCurate was formed by Monash and Melbourne Universities in conjunction with the Victorian State Government specifically to improve the drug commercialisation success It has assembled a team of international experts with demonstrated success in drug discovery and development and is a useful resource for the local research community.


Head and shoulders image, Dr C. Glenn Begley

Dr C. Glenn Begley

Dr Begley is the inaugural CEO of BioCurate. He served as Chief Scientific Officer at Akrivea Therapeutics, California (2016-2027) and TetraLogic Pharmaceuticals, Pennsylvania (2012-2016).  From 2002-2012, he was Vice-President and Global Head of Hematology/Oncology Research at Amgen, responsible for building, directing and integrating Amgen’s 5 research sites.   While at Amgen, he highlighted the issue of research integrity and scientific reproducibility.  Since then he has presented to President Obama's Science Council, the White House, US National Institutes of Health, US Academies of Science, US National Institute of Standards and Technology, the British Broadcasting Company, the Wellcome Trust, Australian National Health and Medical Research Council, and numerous Universities, Research Institutes and companies.

Before Amgen he had over 20 years of clinical experience in medical oncology and haematology.  His personal research focused on regulation of hematopoietic cells and translational clinical trials.  His early studies first described human G-CSF, and in later clinical studies, first demonstrated that G-CSF-"mobilised" blood stem cells hastened hematopoietic recovery. This finding revolutionised the clinical approach to bone-marrow transplantation.

His honours include being elected as the first Foreign Fellow to the American Society of Clinical Investigation in 2000, to the Association of American Physicians in 2008, to the Research "Hall of Fame" at his alma mater, The Royal Melbourne Hospital.

Can't attend in person? Register for Webinar